Rankings / Weight Loss — Incretins & Amylin
Liraglutide
Weight loss · GLP-1 agonist
Tier B
What this is
Earlier-generation GLP-1 (FDA approved 2010). SCALE trial: ~8% weight loss. LEADER trial: 13% MACE reduction in T2D with CVD. Now largely superseded by weekly semaglutide and tirzepatide in the obesity/weight loss space.
Mechanism
Daily GLP-1 receptor agonist; same mechanism as semaglutide; shorter half-life requires daily dosing
Dose & route
Saxenda (obesity): 3.0 mg SC daily; Victoza (T2DM): 0.6-1.8 mg SC daily
Citations
- https://www.nejm.org/doi/full/10.1056/NEJMoa1411892
- https://www.nejm.org/doi/full/10.1056/NEJMoa1603827
- https://pubmed.ncbi.nlm.nih.gov/26132939/
Links go to the source. If a link is dead or you want something re-checked, let me know.
This is an independent synthesis of published research by a non-clinician. Scores are opinions supported by citations, not prescriptions. See the full disclaimer and methodology for how this score was produced and what it does and doesn't mean.